Hospices warn of cuts after 'difficult' 2025

Regional hospices warn of service reductions as statutory funding from the NHS fails to keep pace with rising costs — Jessie May Hospice reported a 17% rise in costs in 2025 while many hospices receive roughly one-third of funding from the NHS and rely on donations for the remainder. The government pledged £100m in 2024 and is developing a new hospice funding model and a palliative care framework, but charities say current support is running out and wage, national insurance and utility inflation are rapidly compressing margins, creating operational and service-delivery risks for vulnerable patients.

Analysis

Market structure: Charities and small regional hospice operators are the clear losers — many get ~1/3 of revenue from NHS and reported input-cost inflation of ~17% in 2025, squeezing margins and forcing service cuts. Winners are large, capitalised providers and staffing/outsourcing businesses that can scale pricing or redeploy nurses (private care operators, staffing agencies, large hospital chains). The £100m government pledge is immaterial to systemic funding shortfalls, so expect consolidation and pricing power to shift toward larger chains over 6–24 months.

Risk assessment: Tail risks include rapid closure of hospices (operational contagion) that forces incremental acute NHS spend (outsized political response), or a funding-model reform that re-prices reimbursements. Immediate window (days–weeks): volatility around any government statement; short-term (1–3 months): donation seasonality and wage rounds; long-term (3–24 months): potential structural consolidation and persistent wage-driven cost inflation. Hidden dependency: donations correlate with consumer confidence — a macro downturn could accelerate closures.

Trade implications: Favor defensive pharma/healthcare large-caps and healthcare ETFs while underweight small-cap UK care operators and charity-linked credit. Expect modest upward pressure on sterling real yields (5–15bp) if government increases statutory support; buy linkers as inflation-hedge. Use options to express asymmetric views: buy call spreads on global pharma; buy put spreads or short equity exposure in small UK care names to capture margin compression over next 3–12 months.

Contrarian angles: Market may underappreciate M&A interest — private equity likely to step in to buy distressed hospices, creating takeover opportunities in 6–18 months. Also, if the government framework standardises funding, larger operators with billing/administration scale (and clean balance sheets) could gain share faster than markets expect; selectively rotate into scaled providers on any policy clarity pullback.

Key Decisions for Investors

• Establish a 2.5% portfolio long in global defensive healthcare: 1.5% AstraZeneca (AZN) and 1.0% GlaxoSmithKline (GSK) to hedge UK social-care volatility; target 12–18 month hold, trim into +15% upside, stop-loss -12%.
• Allocate 1.5% short exposure to small-cap UK care operators (e.g., CareTech Holdings CTH.L) via stock or synthetic short; target 20–35% downside over 3–12 months as wage/utility inflation compresses margins, stop-loss +15% against entry.
• Purchase 3–6 month call spreads on AZN (buy ATM call, sell +10% call) sized at 0.5% notional to capture upside if policy support boosts pharma procurement; keep cost below 0.25% portfolio risk per spread.
• Rotate 1–2% into UK inflation-linked gilts (index-linked) on any real-yield move > +10bp relative to current levels as a hedge vs wage-driven CPI; if real yield > 0.0% buy, target 12–36 month hold.
• Trigger-based action: Monitor Department of Health publication (expected within 30–90 days). If framework increases statutory funding materially (>10% uplift expectation), buy 2–3% positions in scaled UK care operators (e.g., SPI.L Spire) within 1 week and cover shorts; if no meaningful support, add to short positions.